Combination therapy with amlodipinevalsartan in essential hypertension: A 52-week, randomised, open-label, extension study

International Journal of Clinical Practice

Volumn 64, Issue 10, 2010, Pages 1367-1374

  Smith, T R ^a   Glazer, R D ^b   Koren, M J ^c   Wernsing, M ^b   Zhang, Y ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Jacksonville Center for Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE PLUS VALSARTAN; HYDROCHLOROTHIAZIDE; AMLODIPINE; AMLODIPINE, VALSARTAN DRUG COMBINATION; ANTIHYPERTENSIVE AGENT; TETRAZOLE DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ESSENTIAL HYPERTENSION; FEMALE; HEART INFARCTION; HUMAN; HYPOTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL EDEMA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYNCOPE; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; ADOLESCENT; AGED; DOSE RESPONSE; DRUG COMBINATION; HYPERTENSION; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955779262     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02480.x     Document Type: Article

References (21)

1. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005 365 : 217 23.
2. Israili ZH, Hernández-Hernández R, Valasco M. The future of antihypertensive treatment. Am J Ther 2007 14 : 121 34.
3. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003 289 : 2560 72.
4. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Pressure 2009 18 : 308 47.
5. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006 47 : 345 51.
6. Kjeldsen SE, Aksnes TA, Sierra ADL, Ruilope LM. Amlodipine and valsartan: calcium channel blockersangiotensin II receptor blockers combination for hypertension. Drug Eval 2007 4 : 31 40.
7. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002 62 : 443 62.
8. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): multicenter Randomized Controlled Trial. Lancet 2005 366 : 895 906.
9. Bangalore S, Shahane A, Parkar S, Messerli FH. Compliance and fixed-dose combination therapy. Curr Hypertens Rep 2007 9 : 184 9.
10. Basile J. The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens (Greenwich) 2004 6 : 621 9.
11. Philipp T, Smith TR, Glazer R et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild-to-moderate essential hypertension. Clin Ther 2007 29 : 563 80.
12. Philipp T, Glazer RD, Zhao Y, Pospiech R. Long-term tolerability and efficacy of the combination of amlodipinevalsartan in hypertensive patients: a 54-week, open-label extension study. Curr Med Res Opin 2009 25 : 187 93.
13. Hall J, Marbury T, Gray J et al. Long term safety, tolerability and efficacy of valsartan: results from one and two year trials. J Clin Res 1998 1 : 147 59.
14. Tyler HM. Amlodipine: an effective once-daily antihypertensive agent. J Hum Hypertens 1991 1 : 61 6.
15. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999 353 : 611 6.
16. He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J 1999 138 : 211 9.
17. Wolf-Maier K, Cooper RS, Kramer H et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004 43 : 10 7.
18. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients. N Engl J Med 2008 359 : 2417 28.
19. Calhoun DA, Lacourcière Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009 54 : 32 9.
20. Elliott WJ. Is fixed combination therapy appropriate for initial hypertension treatment? Curt Hypertens Rep 2002 4 : 278 85.
21. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007 120 : 713 9.